Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel/Prednisone +/- Enzalutamide in CRPC
NCT02685267Phase 2Terminated
- Sponsor
- Prostate Cancer Clinical Trials Consortium
- Start
- Feb 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by Prostate Cancer Clinical Trials Consortium. Started Feb 2016; status: terminated.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02685267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685267.